The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


CIS bio InternationalEU/1/97/057/001

Main Information

Trade NameQuadramet
Active SubstancesSAMARIUM (153SM) EDTMP
Dosage FormSolution for injection
Licence HolderCIS bio International
Licence NumberEU/1/97/057/001

Group Information

ATC CodeV10BX Various pain palliation radiopharmaceuticals
V10BX02 samarium (153Sm) lexidronam


License statusAuthorised
Licence Issued05/02/1998
Legal statusProduct subject to Restricted Prescription (C)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing Status


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back